Cargando…
A Nonprofit Drug Development Model Is Part of the Antimicrobial Resistance (AMR) Solution
Antibiotics underpin modern medicine and are critical for pandemic preparedness. Push funding has revitalized the preclinical antimicrobial resistance (AMR) pipeline and government funding via CARB-X and BARDA, as well as private sector–led investment via the AMR Action Fund, will help several new a...
Autores principales: | Piddock, Laura J V, Paccaud, Jean-Pierre, O’Brien, Seamus, Childs, Michelle, Malpani, Rohit, Balasegaram, Manica |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9155596/ https://www.ncbi.nlm.nih.gov/pubmed/34618892 http://dx.doi.org/10.1093/cid/ciab887 |
Ejemplares similares
-
Antimicrobial resistance (AMR) as a form of human–wildlife conflict: Why and how nondomesticated species should be incorporated into AMR guidance
por: Mitchell, Jessica
Publicado: (2023) -
Data Sharing Goals for Nonprofit Funders of Clinical Trials
por: Coetzee, Timothy, et al.
Publicado: (2021) -
More Efficient Ways of Assessing Treatments for Neglected Tropical Diseases Are Required: Innovative Study Designs, New Endpoints, and Markers of Effects
por: Olliaro, Piero, et al.
Publicado: (2012) -
The Nonprofit Fundraising Solution
por: Pagnoni, Laurence
Publicado: (2013) -
AMR and Covid-19 on the Frontline: A Call to Rethink War, WASH, and Public Health
por: Zeitoun, Mark, et al.
Publicado: (2021)